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Abstract
Background
Antitachycardia pacing (ATP) is an effective treatment for ventricular tachycardia (VT). We
evaluated the efficacy of different ATP programs based on a large remote monitoring data
set from patients with implantable cardioverter-defibrillators (ICDs).
Methods
A dataset from 18,679 ICD patients was used to evaluate the first delivered ATP treatment.
We considered all device programs that were used for at least 50 patients, leaving us with 7
different programs and a total of 32,045 episodes. We used the two-proportions z-test (α =
0.01) to compare the probability of success and the probability for acceleration in each
group with the corresponding values of the default setting.
Results
Overall, the first ATP treatment terminated in 78.4%–97.5% of episodes with slow VT and
81.5%–91.1% of episodes with fast VT. The default setting of the ATP programs with the
number of sequences S = 3 was applied to treat 30.1% of the slow and 36.6% of the fast epi-
sodes. Reducing the maximum number of sequences to S = 2 decreased the success rate
for slow VT (P < 0.0001, h = 0.38), while the setting S = 4 resulted in the highest success
rate of 97.5% (P < 0.0001, h = 0.27).
Conclusion
While the default programs performed well, we found that increasing the number of
sequences from 3 to 4 was a promising option to improve the overall ATP performance.
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Introduction
Implantable cardioverter-defibrillators (ICDs) are recommended in patients with various
types of heart diseases in order to prevent sudden death and prolong life [1–3]. Antitachycar-
dia pacing (ATP) automatically applied by implantable cardioverter-defibrillators (ICDs)
effectively and painlessly terminates ventricular tachycardia (VT) with low risk of acceleration
[4–6]. The type and parameters of the pacing are programmable; however, in practice, the
default values are often used. The first treatment is often a burst. A burst consists of several
sequences of pulse trains. In the default programming, three sequences are delivered, where
each sequence consists of eight impulses with a constant coupling interval of 88% (i.e., the
cycle length is 88% of the tachycardia cycle length) [4, 7].
The goal of this study was to evaluate the efficacy of different ATP programs and find possi-
ble options for more effective default programming of the devices. Since ATP is very effective, it
is difficult to reliably measure differences between programs on small sample sizes. Further-
more, due to a large number of parameters important for device programming and the complex
interaction between parameters, it is challenging to systematically assess the efficacy of different
settings. Thus, instead of looking at a few patients and parameter variations in a clinical trial, we
analyzed remote monitoring data from unselected patients. This allowed us to consider many
patients and VT episodes and to focus on programming that is used in routine clinical practice.
The downside of our approach is that we had to base our study on anonymized data. Thus,
we could not include possible confounding variables in our analysis, and therefore, the results
should be validated independently in medical trials.
Method
Antitachycardia pacing
In the following, we briefly describe the considered ATP therapy delivered by the ICD. The
device uses electrical leads to monitor heart rhythm by observing features such as the cycle
length, which is the time between two heartbeats, and the heart rate regularity. If a VT or ven-
tricular fibrillation (VF) is detected, a series of ATP therapies are provided. Each ATP therapy
consists of ATP sequences, as shown in Fig 1.
Fig 1. Schema of an ATP therapy.
https://doi.org/10.1371/journal.pone.0219533.g001
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In this study, we focus on the ATP type burst, which is illustrated in Fig 2. Each ATP
sequence consists of several (typically 6–10) stimuli (pulses). The time between the two pulses
is called the interval time. The interval time is given by the detected cycle length multiplied by
a factor called the coupling interval, which we refer to as %R-S1 in accordance with the docu-
mentation of the devices considered in this study. After each ATP sequence, it is checked if the
VT/VF has been terminated. If not (i.e., in case of a re-detection), treatment continues based
on the settings of the ICD, for example, by giving another ATP sequence.
In the burst setting, the newly computed interval time is decreased by a fixed Interval decre-
ment with every sequence, see Fig 2 for an example.
Study population
This study is based on data from 18,679 ICDs (Medtronic) implanted in the U.S.A. in the per-
iod ranging from 2005 to 2016 [8]. The device data were collected in the de-identified Medtro-
nic DiscoveryLink database, and all patients consented to the use of their data for research
purposes. Data from the same population were used for developing a machine learning algo-
rithm for predicting electrical storm by Shakibfar et al. [8].
Fig 2. Schema of a burst ATP therapy. Shown are three sequences, with P = 7 pulses. The interval time between pulses is given by the detected cycle
length times the coupling interval (%R-S1) minus an interval decrement for each repetition.
https://doi.org/10.1371/journal.pone.0219533.g002
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Among all ICD patients, 3,341 ICDs recorded at least one VT. For each VT episode
detected, we looked at the first delivered ATP treatment, which was in almost all cases of the
type burst (> 95%), so other ATP types were discarded. Episodes, where the SmartMode
option was activated, were also discarded because this setting changes the treatment based on
previous success (causing a problem for proper statistical evaluation). The remaining 58,321
episodes from 1,850 devices were grouped by the median cycle length into slow VT (320–
500ms, 46,365 episodes), fast VT (240–320ms, 9,424 episodes), and VF (< 240 ms, 4 episodes)
[4, 6, 9]. The VF group was excluded from the analysis due to the small sample size. See Fig 3
for an illustration.
We considered all device programs that were used for at least 50 patients, leaving us with
seven different programs and a total of 32,045 episodes.
The variable parameters were the coupling interval (%R-S1), the number of stimuli/pulses
per burst (P), and the maximum number of sequences/bursts delivered to treat the VT (S). All
programs used a cycle length interval decrement of 10 ms between sequences.
Statistical evaluation
We counted the episodes where the first ATP treatment successfully terminated VT and those
where the treatment accelerated the heart rate. Termination and acceleration were assessed by
the device after remeasuring the median cycle length. We used the two-proportions z-test (α =
0.01)to compare the probability of success and the probability of acceleration in each group
with the corresponding values of the default setting %R-S1 = 88, S = 3, and P = 8. Large sample
ICDs (N = 18,679)
Burst-ATP & No Smart-Mode (N = 1,850)
Recorded VT (N = 3,341)
Extract VT-Episodes (N = 58,321)
CL: < 240ms
N = 4
CL: 320-500ms
N = 46,365
CL: 240-320ms
N = 9,424
Group at median-CL
Discard Extract programmings with > 50 devices
Fig 3. Chart of dataset generation.
https://doi.org/10.1371/journal.pone.0219533.g003
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sizes allow detecting very small differences between distributions with high probability. How-
ever, very small differences may not be important in practice although they are statistically sig-
nificant. The relevance of the differences can be quantified by measuring the effect size, for
example, using Cohen’s h [10]. To exclude irrelevant effects, we do not discuss significant dif-
ferences with an effect size below h = 0.2 [10], which is the common threshold for small effect
size.
Results
The seven types of programs considered and their success rates for treating slow and fast VTs
for a given setting of the device parameters are given in Fig 4. Overall, the first ATP treatment
terminated in 78.4%–97.5% of episodes with slow VT and in 81.5%–91.1% of episodes with
fast VT.
The default setting %R-S1 = 88, S = 3, P = 8 was applied to treat 30.1% of the slow and
36.6% of the fast episodes. Using more pulses (P = 10) in this setting had no effect. However,
reducing the maximum number of sequences to S = 2 decreased the success rate for slow VT
(P< 0.0001, h = 0.38), while the setting S = 4 resulted in the highest success rate of 97.5%
(P< 0.0001, h = 0.27). In contrast and somewhat surprisingly, for %R-S1 = 84, increasing the
number of sequences from 2 to 3 did not lead to an improvement.
While %R-S1 = 81, S = 3, P = 8 was significantly worse in terminating VT in slow and fast
episodes (P< 0.0001), the effect sizes when reducing %R-S1 were very small (h much smaller
than 0.2).
Fig 4. The fraction of terminated episodes for the different parameter settings for fast and slow VT. The settings differ in the coupling interval (%R-S1), a
maximum number of sequences (S), and the number of pulses (P). The numbers above the bars are from top to bottom: number of patients (n), number of episodes (l),
percentage of episodes where the first ATP treatment terminated VT, and the probability of acceleration. Results significantly better than %R-S1 = 88, S = 3, and P = 8
(P<0.01) are marked by ", significantly worse results are marked by #, and no arrow indicates non-significant differences compared to %R-S1 = 88, S = 3, and P = 8.
https://doi.org/10.1371/journal.pone.0219533.g004
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Discussion
The overall success rates of terminating VT with ATP were slightly higher than those reported
in the literature [4, 6]. As pointed out by Wathen [6], one reason for a higher success rate is a
larger S, which was, for example, set to S = 1 and S = 2 in the PainFREE Rx I and Rx II studies,
respectively [4, 6]. The probability of acceleration ranged from 0.5% to 6.3% with fast VTs hav-
ing higher acceleration risks.
There are limitations to this kind of large-scale studies. There is a lack of information on
the clinical characteristics of the patients studied. Device-based interpretation of ATP success
was used, no manual verification was performed. ICD therapy is initiated so quickly that it is
impossible to separate an arrhythmia into a sustained (duration 30 seconds or more) vs. a
non-sustained arrhythmia (duration less than 30 seconds). This precludes the consideration of
the inappropriate ATP due to SVT or spontaneous termination of VT irrespective of applied
ATP. Although one would assume that inappropriate ATP and spontaneous VT termination
are equally distributed among the groups, they may play a role in smaller subgroups.
Since ICDs can deliver inappropriate therapy (often given to atrial fibrillation), assurance
of correct arrhythmia diagnosis with the verification of ventricular arrhythmia is desirable. We
must assume that a limited number of the episodes in this study were inappropriately diag-
nosed as VT/VF. All patients in the study were US patients, which may have influenced the
strategy of device programming [11].
In conclusion, the default programming performed well. Increasing the number of
sequences from 3 to 4 at %R-S1 = 88 and P = 8 increased the probability of terminating a slow
VT episode without increasing the risk of acceleration or worsening the performance for fast
episodes. Higher pacing frequencies (%R-S1 = 81) were not beneficial. These findings should
be confirmed and further studied in clinical trials.
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